LGM 2605

Drug Profile

LGM 2605

Alternative Names: LGM-2605

Latest Information Update: 28 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator The Scripps Research Institute; University of Pennsylvania
  • Developer LignaMed; National Institute of Allergy and Infectious Diseases
  • Class Antifibrotics; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Lung disorders; Pulmonary fibrosis
  • No development reported Chemotherapy-induced damage; Radiation injuries

Most Recent Events

  • 28 Mar 2018 No recent reports of development identified for preclinical development in Chemotherapy-induced-damage(Prevention) in USA (Intranasal)
  • 28 Mar 2018 No recent reports of development identified for preclinical development in Chemotherapy-induced-damage(Prevention) in USA (IV)
  • 28 Mar 2018 No recent reports of development identified for preclinical development in Chemotherapy-induced-damage(Prevention) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top